PET-CT scan test to assess body inflammation in children
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This Phase 3 study tests whether a special PET-CT scan tracer (fluorodeoxyglucose, or FDG) can better detect and measure a child’s suspected or confirmed histiocytosis. It also checks how safe the scan is, and how well the results match what doctors find.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old at the time of joining
- Your child has confirmed or suspected histiocytosis based on prior test results
- A parent/guardian can sign informed consent for the study
- The child is not currently pregnant (this mainly applies if the participant can become pregnant)
- There are no other major health problems or unusual lab test results that could make the scan unsafe or confuse the results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a PET-CT scan using a small amount of tracer (FDG) can help doctors better identify invasive fungal infections inside the body. It may be useful for guiding diagnosis when standard information is unclear.
This Phase 2 study tests whether a PET/CT scan using a radioactive tracer can help evaluate acute heart inflammation. It may help doctors better identify inflammation and guide follow-up, especially in people suspected of specific heart inflammation conditions or recently after heart transplant follow-up.
This Phase 1 study tests whether a new PET imaging tracer (a small amount of radioactive medicine) is safe and how it moves through the body. It’s mainly for adults with cancer who have signs of inflammation or possible immune side effects, so doctors can see what’s happening in the body.
This trial looks at an imaging scan called CXCR4-targeted PET/CT to help doctors see certain blood cancers. You may be helped by getting clearer information about where cancer is in your body, and the results may guide future care.
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
Hear when a new Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.